New indication for J&J's Remicade approved by FDA

05/19/2005 | Bloomberg Businessweek

The FDA approved Johnson & Johnson's Remicade for reduction of psoriatic arthritis, putting the product in competition with Amgen's blockbuster arthritis drug Enbrel. Both drugs already are approved for treatment of other inflammatory diseases such as rheumatoid arthritis and ankylosing spondylitis.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC